How can I increase my high‑density lipoprotein (HDL) cholesterol?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 12, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

How to Increase HDL Cholesterol

The most effective strategy to raise HDL cholesterol combines regular aerobic exercise (at least 150 minutes weekly of moderate-intensity activity), weight loss if overweight, smoking cessation, and dietary modifications that replace saturated fats with monounsaturated fats—this combination can increase HDL-C by 10-13%. 1, 2, 3

Lifestyle Interventions (First-Line Approach)

Exercise (Most Effective Single Intervention)

  • Engage in aerobic exercise totaling 1,500-2,200 kcal/week of energy expenditure (approximately 25-30 km of brisk walking weekly), which increases HDL-C by 3.1-6 mg/dL (0.08-0.15 mmol/L). 4, 1, 5
  • Aim for at least 30 minutes of moderate-intensity aerobic activity, 5 times weekly, combined with resistance training for optimal results. 1, 2
  • For patients with dyslipidemia, progress to higher intensity aerobic exercise at 85% maximum heart rate and moderate-to-high intensity resistance training at 75-85% of 1RM for greater improvements. 1

Weight Management

  • Each kilogram of sustained weight loss increases HDL-C by 0.4 mg/dL (0.01 mmol/L) once weight stabilizes. 4, 5
  • Target a BMI of 18.5-24.9 kg/m². 1, 2

Smoking Cessation

  • Quit smoking immediately—this single intervention can increase HDL-C by up to 30%. 4, 1, 2, 5

Dietary Modifications

  • Replace saturated fats (limit to <7% of total calories) with monounsaturated fats (olive oil, avocados, nuts) or polyunsaturated fats rather than increasing carbohydrates, which can lower HDL-C. 4, 1, 2
  • Completely avoid trans-unsaturated fatty acids (<1% of energy), as they actively lower HDL-C. 4, 1
  • Minimize refined carbohydrates and added sugars—high-carbohydrate diets decrease HDL-C by 0.1 mmol/L (4 mg/dL) for every 10% energy substitution from fat. 4, 5
  • Choose carbohydrate-rich foods with low glycemic index and high fiber content to minimize HDL-C reduction. 4
  • Consume more than 10 g of soluble fiber daily from legumes, fruits, vegetables, and whole grains. 4, 2, 5
  • Eat fish, especially oily fish, at least twice weekly for omega-3 fatty acids. 1, 2

Alcohol Consumption

  • Moderate alcohol consumption (up to 20-30 g/day in men, 10-20 g/day in women) is associated with increased HDL-C levels compared to abstainers, though this must be balanced against other health risks. 4, 5

Pharmacological Interventions (When Lifestyle Is Insufficient After 3-6 Months)

Primary Target: LDL-C First

  • The primary target of therapy remains LDL cholesterol—HDL-C raising becomes a secondary priority only after achieving LDL-C goals. 4
  • ATP III does not specify a specific HDL-C raising goal, as evidence for targeted HDL-C therapy remains insufficient. 4

Niacin (Nicotinic Acid) - First-Line Pharmacological Option

  • Niacin is the most effective drug for raising HDL-C (increases by 25-35% at highest doses) and has demonstrated coronary heart disease risk reduction in randomized trials both as monotherapy and combined with statins. 1, 6
  • Low doses (≤2 g/day) have minimal effect on glycemic control in diabetic patients. 5
  • A sizable minority of patients experience flushing, which limits tolerability. 1
  • Niacin is relatively contraindicated in diabetic patients due to potential adverse effects on blood glucose. 1, 5

Fibrates - Second-Line Option (Preferred in Diabetics)

  • Fibrates (gemfibrozil, fenofibrate) effectively increase HDL-C and reduce triglycerides without adversely affecting glycemic control, making them the preferred agents for diabetic patients. 1, 5
  • Gemfibrozil demonstrated a 34% relative reduction in serious coronary events in the VA-HIT trial among patients with low HDL-C and prior cardiovascular disease. 1
  • Fenofibrate does not interfere with statin metabolism and is safer than gemfibrozil when combined with statins—gemfibrozil substantially increases myopathy risk. 1, 7
  • Initial fenofibrate dosing: 54-160 mg daily with meals, individualized based on response; use 54 mg daily in patients with mild-to-moderate renal impairment. 7

Statins

  • Statins modestly raise HDL-C while primarily lowering LDL-C, and have the greatest evidence for reducing CAD events in patients with low HDL-C. 8

Target HDL-C Goals

  • Aim for HDL-C >40 mg/dL (1.02 mmol/L) in men and >50 mg/dL (1.28 mmol/L) in women. 1, 2, 5

Monitoring Strategy

  • Measure lipid levels annually in adults with diabetes or cardiovascular risk factors, and every 2 years for low-risk individuals. 1, 2
  • Evaluate lifestyle interventions at regular intervals; consider pharmacological therapy at 3-6 months if targets are not achieved. 1, 2

Critical Pitfalls to Avoid

  • Very low-fat diets (<15% energy as fat) paradoxically lower HDL-C—maintain adequate unsaturated fat intake (15-20% of calories). 2, 3
  • High-carbohydrate diets, especially those high in fructose/sucrose, significantly reduce HDL-C. 4, 2
  • Combination therapy with statins plus gemfibrozil carries substantial myositis risk; fenofibrate is safer for combination therapy. 1, 5
  • In diabetic patients, optimize glycemic control first, as better diabetes management improves the overall lipid profile including HDL-C. 5

References

Guideline

Raising HDL Cholesterol through Lifestyle and Pharmacological Interventions

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Strategies to Improve Cholesterol Levels

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Raising HDL Cholesterol

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Research

Emerging strategies for increasing high-density lipoprotein.

The American journal of cardiology, 2006

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.